- Trials with a EudraCT protocol (194)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (9)
194 result(s) found for: Pathogen.
Displaying page 1 of 10.
EudraCT Number: 2011-005721-43 | Sponsor Protocol Number: D4280C00002 | Start Date*: 2012-05-14 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly C... | ||
Medical condition: Complicated Urinary Tract Infections (cUTIs) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) BE (Completed) BG (Completed) DE (Completed) CZ (Completed) SK (Completed) PT (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002014-39 | Sponsor Protocol Number: RTB-101-205 | Start Date*: 2019-08-30 |
Sponsor Name:resTORbio, Inc. | ||
Full Title: A Multicenter, Randomized, Double Blind, Placebo-Controlled, Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the Elderly | ||
Medical condition: Clinically Symptomatic Respiratory Illness in the Elderly | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005722-21 | Sponsor Protocol Number: D4280C00004 | Start Date*: 2012-06-05 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly C... | ||
Medical condition: Complicated Urinary Tract Infections (cUTIs) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) DE (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) PL (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003621-21 | Sponsor Protocol Number: CTBM100DDE04T | Start Date*: 2013-10-09 | |||||||||||
Sponsor Name:Charité University Hospital Berlin | |||||||||||||
Full Title: Prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled, aerosolized Tobramycin (TOBI®) b.i.d. in patients with v... | |||||||||||||
Medical condition: Intensive care unit patients with ventilation-associated pneumonia. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004703-23 | Sponsor Protocol Number: 1424R2131 | Start Date*: 2017-02-09 | ||||||||||||||||||||||||||
Sponsor Name:Shionogi Ltd. | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens | ||||||||||||||||||||||||||||
Medical condition: Hospital acquired pneumonia (HAP)/ventilator associated pneumonia (VAP)/healthcare-associated pneumonia (HCAP) or bloodstream infections/sepsis (BSI/sepsis) caused by carbapenem-resistant Gram-nega... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: ES (Completed) DE (Completed) GR (Completed) GB (Completed) HR (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004886-98 | Sponsor Protocol Number: TOC110978 | Start Date*: 2017-01-24 | |||||||||||
Sponsor Name:GlaxoSmithKline | |||||||||||||
Full Title: A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Safety and Efficacy of Topical Retapamulin Ointment, 1%, versus Oral Linezolid in the Treatment of Secondarily... | |||||||||||||
Medical condition: secondarily-infected traumatic lesions (SITL; excluding abscesses) or impetigo due to methicillin-resistant Staphylococcus aureus (MRSA | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000726-21 | Sponsor Protocol Number: D4280C00006 | Start Date*: 2012-09-11 | ||||||||||||||||
Sponsor Name:AstraZeneca AB | ||||||||||||||||||
Full Title: An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant G... | ||||||||||||||||||
Medical condition: cUTI, Complicated Urinary Tract Infection, cIAI, Complicated intra-abdominal infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GR (Completed) BG (Completed) HU (Completed) IT (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002110-32 | Sponsor Protocol Number: 10-0065 | Start Date*: 2018-06-13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Regents of the University of Michigan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: DMID Protocol Number: 10-0065 OVERCOME Trial: Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Blood stream Infection (BSI) and/or pneumonia due to extensively drug-resistant Gram-negative bacilli (XDR-GNB) including XDR-AB, CRE and XDR-PA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BG (Completed) GR (Ongoing) IT (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003447-29 | Sponsor Protocol Number: DAP-PEDBAC-11-02 | Start Date*: 2013-06-11 | |||||||||||
Sponsor Name:Cubist Pharmaceuticals, Inc. | |||||||||||||
Full Title: A COMPARATIVE EVALUATION OF THE SAFETY AND EFFICACY OF DAPTOMYCIN VERSUS STANDARD OF CARE IN PEDIATRIC SUBJECTS TWO - SEVENTEEN YEARS OF AGE WITH BACTEREMIA CAUSED BY STAPHYLOCOCCUS AUREUS. | |||||||||||||
Medical condition: Bacteremia caused by Staphylococcus Aureus. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) HU (Completed) GR (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002778-19 | Sponsor Protocol Number: DAP-PEDS-07-03 | Start Date*: 2015-06-29 |
Sponsor Name:Cubist Pharmaceuticals, Inc. | ||
Full Title: An Evaluation of the Safety, Efficacy and Pharmacokinetics of Daptomycin in Pediatric Subjects Aged One to Seventeen Years With Complicated Skin and Skin Structure Infections Caused by Gram-Positiv... | ||
Medical condition: Complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-002768-28 | Sponsor Protocol Number: W-5222-301 | Start Date*: 2022-01-04 | ||||||||||||||||
Sponsor Name:Wockhardt Bio AG | ||||||||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-zidebactam vs. Meropenem in the Treatment of Complicated Urinary Tract Infection... | ||||||||||||||||||
Medical condition: Complicated urinary tract infection or acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: LT (Ongoing) BG (Ongoing) PL (Ongoing) EE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004006-96 | Sponsor Protocol Number: D4281C00001 | Start Date*: 2012-12-27 |
Sponsor Name:Astrazeneca AB | ||
Full Title: A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in th... | ||
Medical condition: nosocomial pneumonia (NP), ventilator-associated pneumonia (VAP) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) HU (Completed) GB (Completed) ES (Completed) IT (Prematurely Ended) PL (Completed) BG (Completed) LV (Completed) SI (Completed) LT (Prematurely Ended) GR (Completed) RO (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-003893-97 | Sponsor Protocol Number: D4280C00001 | Start Date*: 2011-12-14 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI) Plus Metr... | |||||||||||||
Medical condition: Complicated Intra-Abdominal Infection (cIAI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PT (Completed) ES (Completed) HU (Completed) BG (Completed) SK (Completed) NL (Completed) LV (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003895-35 | Sponsor Protocol Number: D4280C00005 | Start Date*: 2012-04-11 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole V... | |||||||||||||
Medical condition: Complicated Intra-Abdominal Infection (cIAI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) GR (Completed) ES (Completed) BG (Completed) IT (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003757-33 | Sponsor Protocol Number: 027ic13250 | Start Date*: 2015-04-21 | |||||||||||
Sponsor Name:AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. | |||||||||||||
Full Title: Evaluation of the efficacy and safety of prulifloxacin vs levofloxacin in the treatment of Chronic Bacterial Prostatitis | |||||||||||||
Medical condition: Chronic Bacterial Prostatitis (CBP) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000914-76 | Sponsor Protocol Number: 1409R2121 | Start Date*: 2014-11-24 | |||||||||||
Sponsor Name:Shionogi Inc. | |||||||||||||
Full Title: A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Unc... | |||||||||||||
Medical condition: Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis caused by Gram-negative Pathogens | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) IT (Completed) ES (Completed) DE (Completed) PL (Completed) RO (Completed) HR (Completed) LV (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000599-18 | Sponsor Protocol Number: P903-09 | Start Date*: 2008-03-25 | |||||||||||
Sponsor Name:Cerexa, Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline versus Ceftriaxone in the Treatment of Adult Subjects with Community-Acquired ... | |||||||||||||
Medical condition: Adult Subjects with Community-Acquired Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) DE (Completed) HU (Completed) AT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000546-30 | Sponsor Protocol Number: Rempex-506 | Start Date*: 2015-04-21 | |||||||||||||||||||||||||||||||
Sponsor Name:Rempex Pharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY OF CARBAVANCE (MEROPENEM/RPX7009) VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH SELECTED SERIOUS INFECTIONS DUE TO CARBAPENEM RESISTANT ENTERO... | |||||||||||||||||||||||||||||||||
Medical condition: serious infections, specifically complicated urinary tract infection (cUTI) or acute pyelonephritis (AP), complicated intra-abdominal infections (cIAI), hospital acquired bacterial pneumonia (HABP... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) GR (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000246-34 | Sponsor Protocol Number: 7655A-014 | Start Date*: 2015-09-28 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||
Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/T... | ||
Medical condition: Treatment for hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) EE (Completed) LV (Completed) BG (Completed) PT (Completed) LT (Completed) FR (Completed) ES (Completed) HR (Completed) CZ (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002388-33 | Sponsor Protocol Number: ZKSJ0086 | Start Date*: 2016-09-05 |
Sponsor Name:Friedrich-Schiller-University Jena | ||
Full Title: Therapeutic drug monitoring (TDM) for personalized antibiotic treatment with piperacillin-tazobactam (PipTaz) in patients with febrile neutropenia after myelo-suppressive cytostatic chemotherapy | ||
Medical condition: Patients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactam | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.